Javascript must be enabled to continue!
Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany
View through CrossRef
Background and aimsIn the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. In addition, data from patients with atherosclerotic cardiovascular disease (ASCVD) in diverse regional backgrounds, including the understudied Brandenburg cohort, and various healthcare statuses remain insufficient.MethodsIn this WalkByLab study, Lp(a) levels were monitored in a non-metropolitan cohort (n = 850) in Brandenburg, Germany, comprising 533 patients at high cardiovascular risk and 317 healthy controls. Patients underwent a comprehensive angiological screening, which included blood serum analysis, assessment of medical and family history, cardiovascular risk, and disease status, and evaluation of lifestyle and quality of life. All parameters were evaluated with regard to two groups based on Lp(a) levels: low (<50 mg/dl) and high (≥50 mg/dl).ResultsBrandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.2% vs. 14.8%, p = 0.001). Logistic regression analysis with different characteristics revealed that Lp(a) was an independent risk factor significantly associated with ASCVD (OR 2.26, 95% CI 1.32–3.95, p = 0.003). The high-Lp(a) group showed a higher proportion of patients with coronary artery disease, peripheral artery disease, or cerebrovascular disease compared to the low-Lp(a) group (50% vs. 36.8%; 57.7% vs. 45.8%; 17.6% vs. 9.2%; p = 0.004); also, a higher percentage of patients in the high-Lp(a) group had heart failure (72.8% vs. 53.2%, p = 0.014) and myocardial infarction (24.7% vs. 13.9%, p = 0.001). The high-Lp(a) group exhibited higher rates of statins (63.1% vs. 50.4%, p = 0.003), ezetimibe (14.8% vs. 5.5.%, p = 0.001), and beta-blockers (55.7% vs. 40.7%, p = 0.001) use. Lp(a) levels were found to be independent of physical activity or smoking behavior and did not change over time (12 months).ConclusionsOur study highlights the significance of elevated Lp(a) levels in Brandenburg cardiovascular patients and identifies them as an independent risk factor for ASCVD, which has implications for addressing cardiovascular health of non-metropolitan populations.
Title: Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany
Description:
Background and aimsIn the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor.
In addition, data from patients with atherosclerotic cardiovascular disease (ASCVD) in diverse regional backgrounds, including the understudied Brandenburg cohort, and various healthcare statuses remain insufficient.
MethodsIn this WalkByLab study, Lp(a) levels were monitored in a non-metropolitan cohort (n = 850) in Brandenburg, Germany, comprising 533 patients at high cardiovascular risk and 317 healthy controls.
Patients underwent a comprehensive angiological screening, which included blood serum analysis, assessment of medical and family history, cardiovascular risk, and disease status, and evaluation of lifestyle and quality of life.
All parameters were evaluated with regard to two groups based on Lp(a) levels: low (<50 mg/dl) and high (≥50 mg/dl).
ResultsBrandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.
2% vs.
14.
8%, p = 0.
001).
Logistic regression analysis with different characteristics revealed that Lp(a) was an independent risk factor significantly associated with ASCVD (OR 2.
26, 95% CI 1.
32–3.
95, p = 0.
003).
The high-Lp(a) group showed a higher proportion of patients with coronary artery disease, peripheral artery disease, or cerebrovascular disease compared to the low-Lp(a) group (50% vs.
36.
8%; 57.
7% vs.
45.
8%; 17.
6% vs.
9.
2%; p = 0.
004); also, a higher percentage of patients in the high-Lp(a) group had heart failure (72.
8% vs.
53.
2%, p = 0.
014) and myocardial infarction (24.
7% vs.
13.
9%, p = 0.
001).
The high-Lp(a) group exhibited higher rates of statins (63.
1% vs.
50.
4%, p = 0.
003), ezetimibe (14.
8% vs.
5.
5.
%, p = 0.
001), and beta-blockers (55.
7% vs.
40.
7%, p = 0.
001) use.
Lp(a) levels were found to be independent of physical activity or smoking behavior and did not change over time (12 months).
ConclusionsOur study highlights the significance of elevated Lp(a) levels in Brandenburg cardiovascular patients and identifies them as an independent risk factor for ASCVD, which has implications for addressing cardiovascular health of non-metropolitan populations.
Related Results
KEDUDUKAN AHLI BAHASA DALAM PEMBUKTIAN PERKARA PENCEMARAN NAMA BAIK (STUDI PUTUSAN NOMOR: 47/PID.SUS/2019/PN. MGT)
KEDUDUKAN AHLI BAHASA DALAM PEMBUKTIAN PERKARA PENCEMARAN NAMA BAIK (STUDI PUTUSAN NOMOR: 47/PID.SUS/2019/PN. MGT)
<em><span id="page3R_mcid52" class="markedContent"><span style="left: calc(var(--scale-factor)*125.30px); top: calc(var(--scale-factor)*539.11px); font-size: calc(va...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Renal Lipoprotein (a) Metabolism
Renal Lipoprotein (a) Metabolism
The kidney plays a central role in lipoprotein(a) catabolism, acting as a “cemetery for lipoprotein(a)” through uptake, fragmentation, and excretion.
Direct human evidence comes fr...
Beyond traditional lipid markers: why lipoprotein(a) screening matters
Beyond traditional lipid markers: why lipoprotein(a) screening matters
Aim: To assess the correlation between lipoprotein(a) levels and traditional lipid profile markers in statin-naive men and women without established atherosclerotic cardiovascular ...
Oral Muvalaplin for Lowering of Lipoprotein(a)
Oral Muvalaplin for Lowering of Lipoprotein(a)
ImportanceMuvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effe...
Cardiovascular outcome in patients with high risk cardiovascular events in Nakornping Hospital
Cardiovascular outcome in patients with high risk cardiovascular events in Nakornping Hospital
Objectives Patients with atherosclerosis are at different levels of elevated risk of ischemic events depending on the specific manifestation of the disease and may have varying de...
Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus
Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus
Introduction: Lipoprotein (a) is made up of an atherogenic LDL lipoparticle and a potentially thrombogenic apoprotein a and is therefore responsible for cardiovascular disease. The...

